CLINICAL_TRIALS
trial_result
· 2017-09-20
Clinical Trial Update: Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) [Phase 3]
Summary
Phase 3 trial update on extended-duration betrixaban for prevention of venous thromboembolism in acutely medically ill patients (APEX study).
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Portola Pharmaceuticals | Conditions: Venous Thromboembolism (VTE) | Phase 3 | Status: COMPLETED | Results posted: 2017-09-20